In a joint effort to tackle Alzheimer’s Disease (AD), Technophage in collaboration with ICNAS (Instituto de Ciências Nucleares Aplicadas à Saúde) is developing a diagnostic solution in PET imaging for this overwhelming pathology.

The experience of the company in discovery of  small domain antibodies and GMP production of biologics, allied to the expertise of ICNAS in the  development of radiochemicals including First in Human studies paved the way to a new and exciting project. 
We propose to develop and validate a new commercial biomarker for imaging that will allow a more precise and early diagnosis of AD through detection of beta-amyloid.
This project is a result from a partnership with Medinfar Group and  Recipharm Venture Fund.